Treatment of Wilson's Disease

Wilson's disease is an autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene, leading to toxic copper accumulation in the liver, brain, and other organs. Treatment aims to reduce copper overload and prevent further accumulation (Wilson's Disease, p. 1).

1. Pharmacological Therapy

A. Copper Chelating Agents

These promote urinary excretion of excess copper and are the first-line treatment for symptomatic patients, especially those with significant liver disease.

Drug	Mechanism	Notes
D-Penicillamine	Chelates copper → urinary excretion	First-line historically; significant side effects (nephrotic syndrome, bone marrow suppression, lupus-like reactions, neurological worsening initially)
Trientine (Triethylene tetramine)	Chelates copper → urinary excretion	Better tolerated than penicillamine; preferred when penicillamine is not tolerated

Important: Both penicillamine and trientine are recommended for significant liver disease. Neurological worsening can paradoxically occur at the start of chelation therapy — close monitoring is essential.

B. Zinc Salts

Mechanism: Induces intestinal metallothionein, which blocks copper absorption from the gut.
Agents: Zinc acetate, zinc sulfate, zinc gluconate.
Best suited for:
- Presymptomatic patients (e.g., siblings identified via screening)
- Maintenance therapy after initial de-coppering with chelators
- Pregnant patients (safer profile)
Less potent than chelators — generally not recommended as sole therapy in significant liver disease.

2. Dietary Modification

Avoid copper-rich foods, especially early in treatment:
- Shellfish (especially oysters), liver, mushrooms, nuts, chocolate, dried fruits
Strict dietary restriction alone is insufficient — pharmacotherapy is required.

3. Monitoring During Treatment

Monitoring detects poor compliance, under-treatment, and over-treatment (Wilson's Disease, p. 1):

Parameter	Purpose
24-hour urinary copper excretion	Assess chelation response
Exchangeable copper (REC)	Newer, recommended biomarker for copper load
Liver function tests (LFTs)	Monitor hepatic status
Clinical symptoms	Neurological/psychiatric improvement or worsening
Serum ceruloplasmin	Baseline and follow-up

4. Acute Liver Failure (Wilsonian Acute Hepatic Failure)

Pharmacological therapy alone may be insufficient in acute liver failure.
Liver transplantation is the treatment of choice for:
- Acute Wilsonian hepatic failure (well-defined indication)
- Decompensated cirrhosis unresponsive to medical therapy

Liver transplantation is curative for the hepatic disease and corrects the underlying metabolic defect.

5. Neurological Wilson's Disease

Chelation therapy (penicillamine or trientine) is the mainstay.
Caution: Penicillamine can worsen neurological symptoms initially — some guidelines prefer trientine or zinc for primarily neurological presentations.
Liver transplantation may be considered in selected neurological cases, though evidence is less robust compared to hepatic indications (Wilson's Disease, p. 1).

6. Special Populations

Population	Preferred Approach
Presymptomatic (screen-detected)	Zinc salts or trientine
Pregnant women	Zinc preferred (teratogenicity concerns with high-dose chelators); reduce penicillamine dose if continued
Children	Trientine or zinc; penicillamine used cautiously

Summary Algorithm

Diagnose using Leipzig score, ceruloplasmin, 24h urine copper, liver biopsy copper content, +/- genetic testing.
Symptomatic / liver disease → Start chelation with penicillamine or trientine.
Stable / presymptomatic / maintenance → Transition to or start zinc salts.
Acute liver failure / decompensated cirrhosis → Liver transplantation.
Monitor regularly with urinary copper, REC, and liver tests.

Source: Wilson's Disease (p. 1)

This is a shared conversation. Sign in to Orris to start your own chat.